46.18
+1.46(+3.26%)
Currency In USD
| Previous Close | 44.72 |
| Open | 46.14 |
| Day High | 46.2 |
| Day Low | 46.06 |
| 52-Week High | 62 |
| 52-Week Low | 28.21 |
| Volume | 79.81M |
| Average Volume | 2.8M |
| Market Cap | 3.46B |
| PE | -13.27 |
| EPS | -3.48 |
| Moving Average 50 Days | 47.43 |
| Moving Average 200 Days | 39.37 |
| Change | 1.46 |
If you invested $1000 in SpringWorks Therapeutics, Inc. (SWTX) since IPO date, it would be worth $2,040.21 as of April 28, 2025 at a share price of $46.17. Whereas If you bought $1000 worth of SpringWorks Therapeutics, Inc. (SWTX) shares 5 years ago, it would be worth $1,423.24 as of April 28, 2025 at a share price of $46.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
GlobeNewswire Inc.
16 hours ago
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
GlobeNewswire Inc.
Yesterday at 2:35 PM GMT
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee f
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
GlobeNewswire Inc.
Jan 30, 2025 12:00 PM GMT
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and